Mesothelioma - Pipeline Insight, 2024

Mesothelioma - Pipeline Insight, 2024

DelveInsight’s, “Mesothelioma - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mesothelioma Understanding

Mesothelioma: Overview

Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 – 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue. Any amount of asbestos exposure can cause mesothelioma. However, certain occupations may experience higher rates of exposure. There are four main types of mesothelioma based on tumor location. The most common type is malignant pleural mesothelioma. The pattern of nodal metastases is different from that seen in lung cancer. With malignant pleural mesothelioma, there is a direct local invasion of the lymph nodes. Overall, the involvement of lymph nodes in malignant pleural mesothelioma is not common.

The three types of mesothelioma based on the cell type are epithelioid, sarcomatoid, and mixed. The epithelioid type is associated with better outcomes. The tumor is often multifocal, forming multiple nodules starting with the parietal pleura. Spread occurs locally in the visceral pleura before extending to the chest wall, diaphragm, or mediastinum. Regional lymph node spread begins with the bronchopulmonary or hilar lymph nodes before moving to the carinal, internal mammary or peridiaphragmatic nodes.

After recognizing symptoms, doctors will perform a variety of tests and procedures to confirm a mesothelioma diagnosis. The doctor may then conduct a physical exam to check for any lumps or abnormalities. They may then conduct basic imaging tests, like an X-ray, and blood work. Doctors use basic blood to check a patient’s overall health and organ function. Biopsies are the only way to definitively diagnose mesothelioma.

Treatment for mesothelioma cancer typically involves a combination of therapies. Patients may receive mesothelioma drugs, radiation or surgery. Doctors will determine an individual’s treatment plan based on cancer type, stage and patient characteristics. Researchers are continuously making advancements in mesothelioma treatment. In medical studies called clinical trials, doctors test the safety and efficacy of emerging drugs and treatments. Experimental therapies may be an option for patients who are not responding to traditional types of treatment.

""Mesothelioma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mesothelioma pipeline landscape is provided which includes the disease overview and Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Mesothelioma.

Mesothelioma Emerging Drugs Chapters

This segment of the Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mesothelioma Emerging Drugs

• TR002: Trizell

TR002 (nadofaragene firadenovec) is an investigational gene therapy consisting of an adenovirus containing the gene interferon alfa-2b. It is administered by catheter into the pleural cavity, where the virus enters the cells lining the pleural cavity. Inside the cells, the virus breaks down leaving the active gene to do its work. The internal gene/DNA machinery of the cells picks up the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach turns the patient's own pleural cavity cells into multiple interferon microfactories, enhancing the body's natural defences against the cancer.

• MTG201: Momotaro-Gene

MTG201 is a novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, increased expression of REIC/Dkk-3 gene in normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune suppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well positioned to work synergistically with checkpoint inhibitors such as nivolumab.

The Phase II trial (NCT04013334), which is being conducted at the Baylor College of Medicine in Houston, Texas, is an open-label, single-arm study designed to assess the efficacy, safety and tolerability of intratumoral administration of MTG201 in combination with nivolumab. The trial will enroll up to twelve patients with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy.

• PM8002: Biotheus

PM8002 is a bispecific antibody targeting both PD-L1 and VEGF-A. PD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and enhance cancer growth and metastasis. In the clinical trial study PM8002 showed encouraging antitumor activity and good safety in patients with advanced solid tumors. Currently, the drug is in the Phase II stage of its development for the treatment of Mesothelioma.

• MT-8421: Molecular Templates

MT-8421, along with MT-6402 (PD-L1 Targeting ETB with Antigen Seeding Technology), represents our unique approach to immuno-oncology based on dismantling the TME through direct cell-kill of tumor and immune cells and not only the blocking of ligand-ligand interactions seen with current antibody therapeutics. The ETB approach includes potent destruction of CTLA4+ regulatory T cells (“Tregs”) via enzymatic ribosome destruction, and the mechanism of cell kill is independent of TME. MT-8421 preferentially destroys high CTLA4 expressing Tregs in the TME relative to peripheral Tregs which are lower CTLA4 expressing. Currently, the drug is in the Phase I stage of its development for the treatment of Mesothelioma.

Further product details are provided in the report……..

Mesothelioma: Therapeutic Assessment

This segment of the report provides insights about the different Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Mesothelioma

There are approx. 50+ key companies which are developing the therapies for Mesothelioma. The companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, Trizell.

• Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mesothelioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mesothelioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mesothelioma drugs.

Mesothelioma Report Insights

• Mesothelioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mesothelioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mesothelioma drugs?
• How many Mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mesothelioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mesothelioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Molecilar Templates
• Trizell
• Momotaro-Gene
• Biotheus
• Lubris Biopharma
• Amphera
• Momotaro-Gene Inc.
• Kissei Pharmaceutical Co., Ltd.
• Novartis Pharmaceuticals
• Oncovir, Inc.
• Sumitomo Dainippon Pharma Oncology
• Bayer
• Hutchison Medipharma Limited
• Targovax
• Polaris Group
• Epizyme, Inc.
• Sanofi
• AstraZeneca
• Vivace Therapeutics, Inc
• Ascentage Pharma Group Inc.
• Shionogi
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Seagen Inc.
• Eli Lilly and Company
• Incyte Corporation

Key Products

• MT-8421
• TR002
• MTG201
• PM8002
• MesoPher
• MTG201
• YS110
• IAG933
• Poly-ICLC
• BBI608
• Anetumab ravtansine
• CPI-0209
• XmAb20717
• HMPL-453
• INBRX-109
• SO-C101
• VMD-928 300
• NGM707
• ONCOS-102
• iCasp9M28z
• Niraparib
• ADI-PEG 20
• VT3989